Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA budget

This article was originally published in The Tan Sheet

Executive Summary

Senate vote on agriculture approps bill expected Oct. 18. Conference report on HR 4461 passed House by a 340-75 vote Oct. 11. Bill provides FDA with $1.22 bil. for fiscal 2001, including salaries, expenses and majority of user fees. CDER receives $317.5 mil., with $6.8 mil. earmarked for adverse event monitoring of drugs. AER funding for dietary supplements/foods is removed in conference report, committee says. CFSAN and its field offices are allocated $285.3 mil., a $30 mil. increase over FY 2000 budget. Food center also is granted $1 mil. to fund a joint University of Mississippi dietary supplement research center

You may also be interested in...



Ole Miss Natural Products Center Botanical Safety/Efficacy Research Planned

The University of Mississippi National Center for Natural Products Research will use CFSAN funding to study botanical ingredients' safety and efficacy under a five-year grant program.

Ole Miss Natural Products Center Botanical Safety/Efficacy Research Planned

The University of Mississippi National Center for Natural Products Research will use CFSAN funding to study botanical ingredients' safety and efficacy under a five-year grant program.

Ole Miss Natural Products Center Botanical Safety/Efficacy Research Planned

The University of Mississippi National Center for Natural Products Research will use CFSAN funding to study botanical ingredients' safety and efficacy under a five-year grant program.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS091766

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel